Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
NAGIOS: RODERIC FUNCIONANDO

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

DSpace Repository

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

Show simple item record

dc.contributor.author Asukai, Yumi es_ES
dc.contributor.author Valladares, Amparo es_ES
dc.contributor.author Camps Herrero, Carlos es_ES
dc.contributor.author Wood, Eifiona es_ES
dc.contributor.author Taipale, Kaisa es_ES
dc.contributor.author Arellano, Jorge es_ES
dc.contributor.author Cassinello, Alejo es_ES
dc.contributor.author Sacristán, José Antonio es_ES
dc.contributor.author Dilla, Tatiana es_ES
dc.date.accessioned 2015-06-29T10:34:12Z
dc.date.available 2015-06-29T10:34:12Z
dc.date.issued 2010 es_ES
dc.identifier.uri http://hdl.handle.net/10550/44818
dc.description.abstract BackgroundThe objective of this study was to conduct a cost-effectiveness evaluation of pemetrexed compared to docetaxel in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) for patients with predominantly non-squamous histology in the Spanish healthcare setting.MethodsA Markov model was designed consisting of stable, responsive, progressive disease and death states. Patients could also experience adverse events as long as they received chemotherapy. Clinical inputs were based on an analysis of a phase III clinical trial that identified a statistically significant improvement in overall survival for non-squamous patients treated with pemetrexed compared with docetaxel. Costs were collected from the Spanish healthcare perspective.ResultsOutcomes of the model included total costs, total quality-adjusted life years (QALYs), total life years gained (LYG) and total progression-free survival (PFS). Mean survival was 1.03 years for the pemetrexed arm and 0.89 years in the docetaxel arm; QALYs were 0.52 compared to 0.42. Per-patient lifetime costs were € 34677 and € 32343, respectively. Incremental cost-effectiveness ratios were € 23967 per QALY gained and € 17225 per LYG.ConclusionsPemetrexed as a second-line treatment option for patients with a predominantly non-squamous histology in NSCLC is a cost-effective alternative to docetaxel according to the € 30000/QALY threshold commonly accepted in Spain. es_ES
dc.source BMC Cancer Vol. 10 pp. 26-26 es_ES
dc.title Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.identifier.doi 10.1186/1471-2407-10-26 es_ES
dc.identifier.idgrec 087869 es_ES

View       (799.2Kb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics